Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LYN-PLT Formulation D
- Development stage
- Unknown
- Lead developer
- Lyndra Therapeutics
- Modality
- Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
LYN-PLT Formulation D is a modified-release (MR), extended-release oral drug formulation designed to persist in the stomach for an extended period—up to 7 days. It utilizes a stellate (star-shaped) modular platform, engineered to unfold and remain in the gastric cavity, where it releases drug in a controlled manner before degrading and passing through the gastrointestinal tract. The platform structure allows for longer drug delivery interval and improved bioavailability. The specific mechanism of action and active pharmaceutical ingredient(s) in this formulation are not publicly disclosed, but the technology platform supports broad applications, including central nervous system, infectious diseases, and chronic disease therapeutics. The developer has demonstrated seven-day gastric residence and pharmacokinetics in clinical settings, and the formulation contains less than 300 mg sucrose[1][7][9].
- Brand names
- LYN-PLT Formulation D
- Other names
- LYN-PLT Formulation D
Beyond the preview
Go deeper on LYN-PLT Formulation D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYN-PLT Formulation D.